Results of the VIVIDD trial indicate that it is unclear whether treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin has a beneficial effect on cardiac outcomes among patients with heart failure and type 2 diabetes.

Results of a study published in JACC: Heart Failure suggest that glycemic control and drug treatment have complex associations with adverse outcomes among patients with heart failure and type 2 diabetes.

Phase II findings show that daily oral semaglutide provides glycemic control that is significantly better than that of placebo and, at the highest doses, is similar to that achieved with weekly injectable semaglutide.

medwireNews provides a brief overview of the published and ongoing glucagon-like peptide-1 receptor agonist cardiovascular outcomes trials.

A partnership between primary care and commercial weight management providers could help reduce the risk for type 2 diabetes among patients with hyperglycemia, UK study findings show.

With four GLP-1 receptor agonists now having published cardiovascular outcome data, medwireNews takes a look at how the experts are interpreting the conflicting findings, and what they mean for prescribing decisions.